California State Teachers Retirement System trimmed its stake in Solventum Corporation (NYSE:SOLV - Free Report) by 28.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 171,548 shares of the company's stock after selling 67,604 shares during the period. California State Teachers Retirement System owned approximately 0.10% of Solventum worth $13,234,928 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. Modus Advisors LLC bought a new position in shares of Solventum during the 4th quarter valued at approximately $30,000. Clearstead Trust LLC lifted its holdings in Solventum by 61.0% during the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company's stock worth $26,000 after buying an additional 150 shares during the last quarter. MV Capital Management Inc. purchased a new stake in Solventum in the 4th quarter valued at approximately $34,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Solventum by 80.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 429 shares of the company's stock valued at $34,000 after buying an additional 191 shares during the period. Finally, Cullen Frost Bankers Inc. grew its position in Solventum by 176.5% in the fourth quarter. Cullen Frost Bankers Inc. now owns 495 shares of the company's stock valued at $39,000 after acquiring an additional 316 shares in the last quarter.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on SOLV shares. BTIG Research reaffirmed a "buy" rating and set a $95.00 price objective on shares of Solventum in a report on Monday. Wall Street Zen raised Solventum from a "hold" rating to a "buy" rating in a research note on Saturday. Wedbush raised their price target on shares of Solventum from $94.00 to $101.00 and gave the stock an "outperform" rating in a research note on Thursday, August 6th. KeyCorp increased their price target on shares of Solventum from $93.00 to $102.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Finally, Weiss Ratings raised Solventum from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, August 18th. Eight equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $92.80.
Check Out Our Latest Research Report on Solventum
Solventum Stock Up 1.4%
Solventum stock traded up $1.25 during midday trading on Tuesday, hitting $91.08. 523,583 shares of the company were exchanged, compared to its average volume of 1,347,636. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74. The company's fifty day moving average price is $85.39 and its 200-day moving average price is $76.69. Solventum Corporation has a fifty-two week low of $62.38 and a fifty-two week high of $94.16. The company has a market cap of $15.50 billion, a PE ratio of 11.14, a price-to-earnings-growth ratio of 1.36 and a beta of 0.61.
Solventum (NYSE:SOLV - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, beating analysts' consensus estimates of $1.91 by $0.64. The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The company's quarterly revenue was up 2.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.69 earnings per share. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, research analysts predict that Solventum Corporation will post 7.22 EPS for the current fiscal year.
Solventum Company Profile
(
Free Report)
Solventum Corporation NYSE: SOLV is a global healthcare company that develops products and technologies intended to improve patient care, support healthcare professionals and increase the efficiency of healthcare delivery. The company serves hospitals, clinics, dental practices, laboratories, government agencies and other healthcare-related organizations.
Its offerings include medical and surgical products such as wound-care, skin-care, infection-prevention and surgical solutions; dental products and materials; and health information systems that support clinical documentation, coding, workflow and decision-making.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
